Phase II APEC trial: The impact of primary tumor side on outcomes of first‐line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild‐type metastatic colorectal cancer

AIM: The open‐label, nonrandomized, phase II APEC study enrolled 167 patients with RAS wild‐type (wt) metastatic colorectal cancer (mCRC) to investigate the safety and efficacy of first‐line, every‐2‐weeks cetuximab plus investigator's choice of FOLFIRI or FOLFOX in this patient population. MET...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Asia Pac J Clin Oncol
Main Authors: Price, Timothy, Shen, Lin, Ma, Brigette, Esser, Regina, Chen, Wenfeng, Gibbs, Peter, Lim, Robert, Cheng, Ann‐Lii
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6852115/
https://ncbi.nlm.nih.gov/pubmed/31090260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajco.13154
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados